SCHEDULE: Cormorant Asset Management Discloses 9.99% Stake in iBio

Cormorant Asset Management and Bihua Chen have disclosed a 9.99% beneficial ownership stake in iBio, Inc., primarily through warrants.

Summary

• Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 2,248,010 shares of iBio, Inc. common stock.
• This represents 9.99% of iBio's outstanding common stock.
• The ownership is primarily derived from shares issuable upon the exercise of pre-funded and/or Series G warrants.
• An exercise limitation prevents the holders from beneficially owning in excess of 9.99% of iBio's common stock.
• Without this limitation, the warrants would be exercisable for up to 8,461,990 shares.
• The reported holdings do not include an additional 3,570,000 shares issuable from a Series H warrant, which is contingent on the exercise of the Series G warrant.
• The percentage is calculated based on 20,254,599 shares of common stock outstanding as of October 3, 2025, as reported in iBio's Schedule 14A.
• Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, holds rights to dividends or proceeds from more than 5% of the shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of iBio.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by a reputable institutional investor like Cormorant Asset Management is generally a positive signal, indicating confidence in iBio. However, the 9.99% beneficial ownership cap and the potential future dilution from warrants introduce some complexity.

Positives

• A significant institutional investor, Cormorant Asset Management, has taken a substantial 9.99% stake in iBio, indicating confidence in the company.
• The investment is structured with warrants, suggesting a long-term view and potential for increased ownership if the exercise limitation is removed or the company's share count grows.

Negatives

• The 9.99% beneficial ownership limit suggests a strategic cap to avoid certain regulatory or governance thresholds, which might limit the investor's direct influence despite a large stake.
• The existence of unexercised warrants (up to 8,461,990 shares from G warrants, plus 3,570,000 from H warrants) represents potential future dilution if exercised, although the 9.99% cap currently limits this.

Risks

• Potential future dilution from the exercise of warrants if the 9.99% beneficial ownership limitation is removed or the company's outstanding shares increase significantly.
• The current beneficial ownership limit of 9.99% might restrict Cormorant's ability to exert greater influence or control over iBio, despite their significant investment.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from iBio, Inc. It primarily discloses current beneficial ownership by Cormorant Asset Management.

Industry Context

The disclosure of a significant stake by Cormorant Asset Management, a specialized healthcare investor, in iBio, Inc. suggests continued institutional interest in the biotechnology sector. Such investments often signal a belief in the long-term potential of the company's pipeline or technology, aligning with broader trends of venture capital and institutional funding flowing into life sciences.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a substantial stake could be viewed positively, potentially boosting investor confidence and signaling long-term interest in iBio. However, the potential for future warrant exercises could lead to dilution.

Key Dates

Recommendation

The disclosure of a significant 9.99% stake by a specialized healthcare investor like Cormorant Asset Management is a positive indicator of institutional confidence in iBio. However, the investment is primarily through warrants with an exercise limitation, and the potential for future dilution from these warrants, while currently capped, warrants a 'hold' recommendation. Investors should monitor iBio's operational performance and any future changes in Cormorant's stake or the warrant terms.

Keywords

iBio Inc, Cormorant Asset Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology, Healthcare Investment